Form 4: Rocket Pharmaceuticals Director Acquires Stock Options

Director Piratip Pratumsuwan acquired stock options for Rocket Pharmaceuticals shares, according to a recent SEC filing.

Summary

• Piratip Pratumsuwan, a director of Rocket Pharmaceuticals, Inc., filed a Form 4 with the SEC.
• The filing reports the acquisition of two stock option grants.
• The first option is for 51,181 shares of common stock, vesting in equal monthly installments over three years, fully vested by February 3, 2028.
• The second option is for 22,443 shares of common stock, fully vesting on February 3, 2026.
• Both options have an exercise price of $10.56.
• Following the reported transactions, Pratumsuwan directly owns 51,181 and 22,443 derivative securities.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a routine filing related to stock option grants, which is a standard practice. It doesn't inherently indicate positive or negative performance, but rather aligns director interests with shareholders.

Positives

• The acquisition of stock options by a director can be seen as a positive sign, indicating confidence in the company's future performance.

Future Outlook

The document does not contain specific forward-looking statements regarding the company's future performance beyond the vesting schedules of the options.

Industry Context

Stock option grants are a common form of compensation for directors and executives in publicly traded companies, particularly in the biotechnology and pharmaceutical industries, aligning their interests with those of shareholders.

Comparison to Industry Standards

• Stock option grants are a standard component of executive compensation packages in the pharmaceutical industry.
• Companies like BioMarin, Sarepta Therapeutics, and CRISPR Therapeutics also utilize stock options to incentivize their leadership teams.
• The vesting schedules and exercise prices are generally aligned with industry norms, aiming to reward long-term value creation.

Stakeholder Impact

• The stock option grants align the director's interests with those of shareholders, incentivizing them to increase the company's value.

Key Dates

Keywords

stock options, Form 4, Rocket Pharmaceuticals, Piratip Pratumsuwan, director, RCKT, acquisition